Day 1

SIGNIFY: Ivabradine does not reduce events in patients with stable coronary disease

solaci
solaci
409
0

The increase in heart rate in the setting of chronic coronary artery disease is associated with poor prognosis, especially increased risk of acute myocardial infarction. Reducing heart rate with ibravadina inhibitor may confer symptomatic benefit of angina and reduce coronary events in patients with chronic coronary disease and a resting heart rate ≥ 70 bpm. After a mean follow up of 27.8 months, no significant difference was observed for the occurrence of events between ibravadina group and the placebo group. 

9_kim_fox
Kim Fox
2014-08-31

Original title: Ivabradine in patients with stable coronary artery disease without clinical heart failure: The results of SIGNIFY.

Previous article
ODYSSEYCOMBO II: Alirocumab more effective than ezetimibe when statins are insufficient
Next article
ODYSSEY FH I and FH II: Alirocumab in patients with heterozygous familial hypercholesterolemia
solaci
solaci

More articles by this author

ODYSSEY LONG TERM: Safety and efficacy of long-term alirocumab

solaci - 0
This was a prospective, randomized, controlled study comparing monoclonal antibody alirocumab with placebo in patients with hypercholesterolemia and high cardiovascular risk. At 24 weeks...

LISTEN: Rosuvastatin versus atorvastatin in Japanese diabetic patients

solaci - 0
The treatment of hyperlipidemia is useful in primary and secondary prevention of chronic heart disease and stroke, particularly in diabetic patients. Many statins may...

COPPS-2: Colchicine for prevention of post-pericardiotomy syndrome and postoperative atrial fibrillation

solaci - 0
180 patients with colchicine 0.5 mg twice daily from 48-72 hs. before surgery versus 180 patients to placebo were randomized. The medication was continued...

ODYSSEY FH I and FH II: Alirocumab in patients with heterozygous familial hypercholesterolemia

solaci - 0
The study included patients with a diagnosis of heterozygous familial hypercholesterolemia who were receiving the maximum tolerated dose of randomized statin alirocumab 75 mg...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

Day 1

ODYSSEY LONG TERM: Safety and efficacy of long-term alirocumab

This was a prospective, randomized, controlled study comparing monoclonal antibody alirocumab with placebo in patients with hypercholesterolemia and high cardiovascular...
solaci -
SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | ALL-RISE Trial: Coronary Physiological Assessment Using FFRangio

Dr. Juan Manuel Pérez - 0
Coronary physiological assessment using pressure-wire techniques (FFR/iFR) carries a Class IA recommendation in ACC/AHA guidelines; however, its use remains limited due to factors such...

ACC 2026 | Protect The Head-To-Head Trial: Randomized Comparison Between Emboliner and Sentinel During TAVI

Dr. Juan Manuel Pérez - 0
Ischemic stroke remains one of the most feared complications of TAVI, with a relatively low but persistent incidence of 2–4%, without significant reduction over...

ACC 2026 | PRO-TAVI Trial: Deferring Coronary Angioplasty in Patients Undergoing TAVI

Dr. Juan Manuel Pérez - 0
Coronary artery disease is common in patients with severe aortic stenosis undergoing TAVI. Current guidelines recommend considering revascularization in significant coronary lesions, particularly in...